Written by Edzard Ernst and the CAM-Cancer Consortium.
Updated April 29, 2016

Shark cartilage

Abstract and key points

  • Medication is made from the cartilage of two shark species
  • There is no good evidence that shark cartilage or ingredients of shark cartilage are of benefit for cancer patients
  • No major safety concerns have been reported

Shark cartilage is a popular anti-cancer remedy, which is obtained from the cartilage of mainly two shark species.

Even though some basic research suggests that shark cartilage has anti-angiogenic and cytotoxic effects, there is no evidence from five controlled and eight uncontrolled studies to show that it is helpful in the treatment of cancer.

Records of adverse effects exist for the oral supplementation of shark cartilage as well as the injection or enema procedure but no serious events are on record.

Citation

Edzard Ernst, CAM-Cancer Consortium. Shark cartilage [online document]. http://cam-cancer.org/The-Summaries/Dietary-approaches/Shark-cartilage. April 29, 2016.

Document history

Assessed as up to date in April 2016 by Barbara Wider.
Most recent update and revision in April 2013 by Edzard Ernst.
Fully revised and updated in November 2011 by Edzard Ernst.
Fully revised and updated in April 2010 by Edzard Ernst.
Summary first published in September 2005, authored by Edzard Ernst.

References

  1. Neovastat clinical trial abstracts. Presented at the American Association for Cancer Research 92nd annual meeting. March 27, 2001.
  2. Batist G, Patenaude F, Champagne P, et al. Neovastat (AE-941) in refractory renal cell carcinoma patients: report of a phase II trial with two dose levels. Ann Oncol 2002;13:1259-63.
  3. Sauder DN, Dekoven J, Champagne P, et al. Neovastat (AE-941), an inhibitor of angiogenesis: Randomized phase I/II clinical trial results in patients with plaque psoriasis. J Am Acad Dermatol 2002;47:535-41.
  4. Hillman JD, Peng AT, Gilliam AC, Remick SC. Treatment of Kaposi Sarcoma with oral administration of shark cartilage in a Human Herpes virus 8-seropositive, Human Immunodeficiency Virus-Seronegative homosexual man. Arch Dermatol 2001;137:1149-52.
  5. Fetrow CW, Avila JR. Professional's Handbook of Complementary & Alternative Medicines. 1st ed. Springhouse, PA: Springhouse Corp., 1999.
  6. Folkman J, Long DM, Becker FF. Growth and metastasis of tumour organ culture. Cancer 1963;16:453-67.
  7. Lane IW. Comac L. Sharks don’t get cancer. How shark cartilage can save your life. New Your: Avery, 1992.
  8. Wellings SR. Neoplasia and primate vertebrate phylogeny: a review. Natl Cancer Inst Monograph 1969;31:59-128.
  9. Prieur DJ, Fenstermaher JD, Guarino AM. A choroids plexus papilloma in Elasmobranchs. J Natl Cancer Inst 1976;56:1207-9.
  10. Cassileth BR Shark and bovine cartilage therapies. In: Cassileth BR, ed.: The Alternative Medicine Handbook: The Complete Reference Guide to Alternative and Complementary Therapies. New York, NY: WW Norton & Company, 1998, pp 197-200.
  11. Prudden J. The clinical acceleration of healing with a cartilage preparation: a controlled study. JAMA 1965;192:252.
  12. Prudden JF, Balassa LL The biological activity of bovine cartilage preparations. Clinical demonstration of their potent anti-inflammatory capacity with supplementary notes on certain relevant fundamental supportive studies. Semin Arthritis Rheum 1974;3: 287-321.
  13. Lee A, Langer R Shark cartilage contains inhibitors of tumor angiogenesis. Science 1983;221:1185-7.
  14. Bargahi A, Rabbani-Chadegani A, Bargahi A et al. Angiogenic inhibitor protein fractions derived from shark cartilage. Biosci Rep 2008;28:15-21.
  15. Folkman J, Klagsburn M. Angiogenic factors. Science 1987;235:442-7.
  16. Hyodo I, Amano N, Eguchi K et al. Nationwide survey on complementary and alternative medicine in cancer patients in Japan. J Clin Oncol 2005;23:2645-54.
  17. Bernstein BJ, Grasso T. Prevalence of complementary and alternative medicine use in cancer patients. Oncology 2001;15:1267-72, 1274-5.
  18. Oneschuk D, Fennell L, Hanson J, Bruera E. The use of complementary medications by cancer patients attending an outpatient pain and symptom clinic. Journal of Palliative Care 1998;14:21-6.
  19. Dold C. Shark therapy. Discover 1996;4:51-7.
  20. Lu C, Lee JJ, Komaki R, Herbst RS, Feng L, Evans WK et al. Chemoradiotherapy with or without AE-941 in stage III non-small cell lung cancer: a randomized phase III trial. Journal of the National Cancer Institute 2010; 102(12):859-865.
  21. Batist G, Champagne P, Hariton C, et al. Dose-survival relationship in a phase II study of Neovastat in refractory renal cell carcinoma patients. [Abstract] Proceedings of the American Society of Clinical Oncology 2002;21:A-1907.
  22. Loprinzi CL, Levitt R, Barton DL, Sloan JA, Atherton PJ, Smith DJ, Dakhil SR, Moore DF Jr, Krook JE, Rowland KM Jr, Mazurczak MA, Berg AR, Kim GP; North Central Cancer Treatment Group. Evaluation of shark cartilage in patients with advanced cancer – a north central cancer treatments group trial . Cancer 2005;104:176-82.
  23. Berbari P, Thibodeau A, Germanin L, Saint-Cyr M, Gaudreau P, Elkhouri S, Dupont E, Garrel DR, Elkouri S. Antiangiogenic effects of the oral administration of liquid cartilage extracts in humans. J Surg Res 1999;87:108-13.
  24. Mathews J. Media feeds frenzy over shark cartilage as a cancer treatment. J Natl Cancer Inst 1993;85:1190-1191.
  25. Barber R, Delahunt B, Grebe SKG, Davis PF, Thornton A, Slim GC. Oral shark cartilage does not abolish carcinogenesis but delays tumor progression in a murine model. Anticancer Research 2001;21:1065-70.
  26. Yagita A. Role of angiogenesis inhibitor in novel immunotherapy for cancer (NITC). BiotherapyJapan 2000;14:973-82.
  27. Maruyama S, Yagita A, Sukegawa Y, Daido A, Takeuchi S. Effect of a new immunotherapy for advanced colorectal cancer. BiotherapyJapan 2000;14:460-3.
  28. Leitner SP, Rothkopf MM, Haverstick L, et al. Two phase II studies of oral dry shark cartilage powder (SCP) with either metastatic breast or prostate cancer refractory to standard treatment. [Abstract] Proceedings of the American Society of Clinical Oncology 1998;17:A-240.
  29. Rosenbluth RJ, Jennis AA, Cantwell S, et al. Oral shark cartilage in the treatment of patients with advanced primary brain tumors. [Abstract] Proceedings of the American Society of Clinical Oncology 1999;18:A-554.
  30. Champagne P, Aeterna Laboratories, Incorporated Phase II Study of AE-941 (Neovastat) in Patients With Early Relapse or Refractory Multiple Myeloma, AETERNA-AE-MM-00-02, Clinical trial, Closed.
  31. Miller DR. Phase I/II trial of the safety and efficacy of shark cartilage in the treatment of advanced cancer. J Clin Oncol 1998;16:3649-3655.
  32. McGuire TR et al. Tamoxifen and shark cartilage: potential anti-angiogenic combination (Abstract from American College of Clinical Pharmacy Annual Meeting St. Louis, 1994). Pharmacotherapy 1994;14:362.
  33. Ashar B, Vargo E. Shark cartilage-induced hepatitis. Ann Intern Med 1996;125:780-781.
  34. Simard B, Bouamrani A, Jourdes P, Pernod G, Dimitriadou V, Berger F et al. Induction of the fibrinolytic system by cartilage extract mediates its antiangiogenic effect in mouse glioma. Microvascular Research 2011; 82(1):6-17.
  35. Bargahi A, Hassan ZM, Rabbani A, Langroudi L, Noori SH, Safari E et al. Effect of shark cartilage derived protein on the NK cells activity. Immunopharmacology & Immunotoxicology 2011; 33(3):403-409.
  36. Habermann TM, Thompson CA, LaPlant BR, Bauer BA, Janney CA, Clark MM et al. Complementary and alternative medicine use among long-term lymphoma survivors: a pilot study. American Journal of Hematology 2009; 84(12):795-798.